Matt Angle
Founder and CEO of Paradromics, developing high-bandwidth brain-computer interfaces that record from individual neurons to restore communication for people with severe paralysis.
Background
Matt Angle, PhD, is the founder and CEO of Paradromics, a neurotechnology company focused on developing high-bandwidth brain-computer interfaces to restore communication and independence for people with severe paralysis from ALS, stroke, and spinal cord injury. Angle was inspired by neural recording research at Stanford University and founded Paradromics in 2015 with the mission to translate cutting-edge neural interface technology from the laboratory into commercial medical devices that patients could use in their daily lives.
Key Contributions
Angle founded Paradromics to develop the Connexus BCI system, designed to record neural signals at unprecedented bandwidth by capturing activity from individual neurons rather than just local populations. The Connexus system uses a high-channel-count electrode array to achieve exceptionally detailed neural recordings, enabling high-performance decoding of intended movements and communication. Paradromics completed its first-in-human recording with the Connexus BCI and received FDA approval for its Connect-One clinical study for speech restoration in people with ALS, representing a significant milestone in translating high-bandwidth BCI technology to clinical practice. Angle’s vision is to develop truly practical BCIs that offer sufficient performance and reliability for everyday clinical use, distinguishing Paradromics from other BCI companies by emphasizing raw signal quality and bandwidth as critical to achieving high-performance neural decoding.
Current Work
Under Angle’s leadership, Paradromics continues to advance its Connexus BCI platform toward clinical applications. The company is conducting FDA-approved human clinical trials focused on speech restoration, with plans to expand to motor control and other applications. Angle’s strategic focus on high-bandwidth neural recording reflects his belief that capturing more neural information at higher fidelity is essential to achieving BCIs with sufficient performance and reliability to transform the lives of people with severe paralysis.